Xenon Pharmaceuticals (XENE)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
Fundamental grade
Five factors scored 1 to 9 from XENE's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from Xenon Pharmaceuticals's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $18M | $9M | $0 | $0 | $8M |
| Net income | -$79M | -$125M | -$182M | -$234M | -$346M |
| Free cash flow | -$72M | -$104M | -$157M | -$184M | -$280M |
| EPS (diluted) | -$1.77 | -$2.06 | -$2.73 | -$3.01 | -$4.36 |
| Operating margin | -428.4% | -1368.9% | — | — | -4974.3% |
Superinvestors who own XENE
From each investor's latest 13F filing (what a 13F shows). 3 of the investors we track hold it.
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| Stanley Druckenmiller Duquesne Family Office |
Held | $14M | 0.28% | Q2 2026 |
| Ron Baron Baron Capital (BAMCO) |
Held | $2M | 0.00% | Q2 2026 |
| Cliff Asness AQR Capital Management |
Trimmed | $438,394 | 0.0% | Q2 2026 |
Insider buying
Open-market purchases by Xenon Pharmaceuticals's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Sep 30, 2026 | Ian Mortimer PRESIDENT & CEO |
30,000 | $37.38 | $1M |
| Sep 30, 2026 | Thomas Patrick Kelly Chief Financial Officer |
15,000 | $37.32 | $559,740 |
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when XENE trades at or below it.
New accounts get 7 days of Pro, price alerts included. No card needed.
In the full deep dive
Questions
Are Xenon Pharmaceuticals insiders buying the stock?
2 open-market insider purchases of XENE in the last 12 months, from SEC Form 4 filings.
Which superinvestors own Xenon Pharmaceuticals?
3 of the superinvestors Investingly tracks hold XENE in their latest 13F, including Stanley Druckenmiller, Ron Baron, Cliff Asness.
Companies like Xenon Pharmaceuticals
All Healthcare stocks · Biotechnology stocks · Stock lists
Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.